局部晚期食管鳞癌患者癌组织SATB1和PRKDC蛋白表达与放化疗敏感性的关系

doi:10.3969/j.issn.1004-616x.2025.04.015

摘要/Abstract

摘要： 目的：探讨局部晚期食管鳞癌患者癌组织特异性AT富集序列结合蛋白1(SATB1)和DNA依赖性蛋白激酶催化亚基(PRKDC)蛋白的表达与放化疗敏感性的关系，以及影响患者放化疗敏感性的其他病理因素。方法：选取30例局部晚期食管鳞癌患者作为研究对象，患者均进行标准根治性放疗和同步化疗。放化疗完成后3个月，参照世界卫生组织(WHO)的实体瘤疗效评定标准(RECIST)评估短期疗效，并根据疗效将患者分为放化疗敏感组(CR+PR)16例和放化疗不敏感组(SD+PD)14例。采用Western blot法检测以上两组标本癌组织中SATB1和PRKDC蛋白的表达水平，同时收集患者性别、年龄、病理分级、临床分期、肿瘤位置、生存情况等临床资料，并分析患者的放化疗敏感性与其临床病理指标的关系。结果： SATB1在放化疗敏感组食管鳞癌患者癌组织中表达水平较不敏感组高(P<0.05)，PRKDC蛋白在食管癌放化疗敏感组和不敏感组中均未见表达。与放化疗不敏感组相比，放化疗敏感组肿瘤分化程度较低，临床分期较早(P<0.05)。敏感组与不敏感组患者的性别、年龄、病变部位和1年生存率的差异无统计学意义(P>0.05)。结论： SATB1蛋白的表达与食管癌放化疗敏感性相关，其表达水平可预测食管癌患者对放疗的敏感性；PRKDC蛋白在食管癌组织中表达缺失。另外，食管癌患者放化疗敏感性还与肿瘤分化程度和临床分期相关。

关键词: 特异性AT富集序列结合蛋白1, DNA依赖性蛋白激酶催化亚基, 食管癌, 放化疗敏感性

Abstract: OBJECTIVE： To study the expressions of special-AT-rich sequence binding protein-1(SATB1) and catalytic subunit of the DNA-dependent protein kinase(PRKDC) protein in advanced esophageal squamous cell carcinomas and their relationship with carcinomas—sensitivity to chemoradiotherapy. METHODS： Thirty patients with locally advanced esophageal squamous cell carcinoma in our hospital were selected as the study subjects. These patients received standard radical radiotherapy and synchronous chemotherapy. Three months after the completion of chemoradiotherapy，the short-term efficacy was evaluated according to the Criteria (RECIST) which classified the patients into two groups： radiotherapy sensitive group (CR+PR) of 16 cases and a chemoradiotherapy insensitive group (SD+PD) of 14 cases. Simultaneously， clinical data such as patient gender，age，pathological grading，clinical staging，tumor location，and survival status were collected. Western Blot assay was used to detect the expression levels of SATB1 and PRKDC proteins in cancer tissues of the patients. Relationships between the expression levels and clinical pathological factors were determined. RESULTS： The PRKDC protein was not expressed in both the sensitive and insensitive groups of carcinomas. Expression levels of SATB1 were higher in the sensitive than the insensitive group (P<0.05). Compared with the insensitive group，the sensitive group had lower tumor differentiation and earlier staging (P<0.05). There was no statistically significant difference in gender，age，lesion location，and 1-year survival between the sensitive and the insensitive groups (P>0.05). CONCLUSION： Our data shows that expression of the SATB1 protein was closely related to the sensitivity of esophageal carcinomas to chemoradiotherapy and to the degree of differentiation. The expression may therefore be useful in predicting efficacy of esophageal carcinomas to chemoradiotherapy. On the other hand，PRKDC protein was not expressed in the cancer tissues.

Key words: SATB1, PRKDC, esophageal cancer, chemoradiosensitivity

中图分类号:

R730.5

阿衣古丽·哈热, 阿布地力·阿布都许库. 局部晚期食管鳞癌患者癌组织SATB1和PRKDC蛋白表达与放化疗敏感性的关系[J]. 癌变·畸变·突变, 2025, 37(4): 314-318.

AYIGULI·Hare, ABUDILI·Abuduxuku. Expression of SATB1 and PRKDC proteins and sensitivity of advanced esophageal squamous cell carcinomas to chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 314-318.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 徐玥, 廖应英, 孙泽群. 食管癌的流行病学特征及发病高危因素研究进展[J]. 中国现代医生, 2024, 62(7): 113-117.
[3] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[4] ZHOU B L, BIE F L, ZANG R C, et al. Global burden and temporal trends in incidence and mortality of oesophageal cancer[J]. J Adv Res, 2023, 50: 135-144.
[5] SOHDA M, ISHIKAWA H, MASUDA N, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer[J]. Int J Cancer, 2004, 110(6): 838-844.
[6] SUN S F, CHENG S G, ZHU Y X, et al. Identification of PRKDC (protein kinase, DNA-activated, catalytic polypeptide) as an essential gene for colorectal cancer (CRCs) cells[J]. Gene, 2016, 584(1): 90-96.
[7] ZHOU Y, LIU F, XU Q Y, et al. Inhibiting importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer[J]. Oncogene, 2020, 39(34): 5633-5648.
[8] SUN-G, YANG-L, DONG-C, et-al. PRKDC regulates chemosen-sitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients[J]. Oncol Rep, 2017, 37(6): 3536-3542.
[9] SIEGEL M J, IPPOLITO J E, WAHL R L, et al. Discrepant assessments of progressive disease in clinical trials between routine clinical reads and formal RECIST 1.1 interpretations[J]. Radiol Imaging Cancer, 2023, 5(5): e230001.
[10] KOBAYASHI Y, SUGIURA T, IMAJYO I, et al. Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle[J]. Int J Oncol, 2014, 44(4): 1107-1117.
[11] WANG J, YU P Y, LUO J D, et al. Transcriptomic and microRNA expression profiles identify biomarkers for predicting neo-chemoradiotherapy response in esophageal squamous cell carcinomas (ESCC)[J]. Front Pharmacol, 2021, 12: 626972.
[12] MEZENCEV R, MATYUNINA L V, JABBARI N, et al. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity[J]. BMC Cancer, 2016, 16: 236.
[13] ZHANG L, KIM S, JIA G X, et al. Exome sequencing of normal and isogenic transformed human colonic epithelial cells (HCECs) reveals novel genes potentially involved in the early stages of colorectal tumorigenesis[J]. BMC Genomics, 2015, 16(Sup 1): S8.
[14] CAI S T, HAN H J, KOHWI-SHIGEMATSU T. Tissue-specific nuclear architecture and gene expression regulated by SATB1[J]. Nat Genet, 2003, 34(1): 42-51.
[15] PANCHAL O, WICHMANN G, GRENMAN R, et al. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)[J]. Sci Rep, 2020, 10(1): 8615.
[16] YE-C-S, ZHOU-D-N, YANG-Q-Q, et al. Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma[J].-Int-J-Clin-Exp-Pathol, 2014, 7(3): 914-922.
[17] 张升, 张士发, 王良民, 等. SIRT1、EZH2和SATB1在皮肤恶性黑素瘤组织中的表达及其临床意义[J]. 临床皮肤科杂志, 2021, 50(3): 138-142.
[18] 龚丹, 瞿伟. E2F5和SATB1在乳腺癌组织中的表达及其对乳腺癌细胞生物学功能的影响[J]. 吉林医学, 2023, 44(5): 1151-1154.
[19] 马博, 周军, 李建刚, 等. SATB1、CBX7表达预测结直肠癌患者术后复发的价值[J]. 中国现代医学杂志, 2022, 32(20): 90-95.
[20] 韦付坤, 阚懿, 刘继海, 等. 特异性核基质结合区结合蛋白1与转录因子E盒结合锌指蛋白1在前列腺癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2021, 38(6): 1067-1070.
[21] 李欢, 董宇曦. AFP、AKT2、SATB1在原发性肝癌患者中的表达水平及与临床病理特征的关系[J]. 国际检验医学杂志, 2022, 43(18): 2274-2278, 2282.
[22] 乔娟, 杨昊, 牛丽红, 等. 干扰SATB1抑制宫颈癌增殖和转移能力及增强宫颈癌放射敏感性的作用研究[J]. 国际检验医学杂志, 2023, 44(21): 2581-2586.
[23] GLATZEL-PLUCI-SKA N, PIOTROWSKA A, DZI-GIEL P, et al. The role of SATB1 in tumour progression and metastasis[J]. Int J Mol Sci, 2019, 20(17): 4156.
[24] JENKE R, HOLZH-USER-REIN M, MUELLER-WILKE S, et al. SATB1-mediated upregulation of the oncogenic receptor tyrosine kinase HER3 antagonizes MET inhibition in gastric cancer cells[J]. Int J Mol Sci, 2021, 22(1): 82.
[25] HUANG B, XIONG F, WANG S W, et al. Effect of SATB1 silencing on the proliferation, invasion and apoptosis of TE-1 esophageal cancer cells[J]. Oncol Lett, 2017, 13(5): 2915-2920.
[26] REN F, YANG Z L, TAN X G, et al. DNA-PKcs and Ku70 are predictive markers for poor prognosis of patients with gall bladder malignancies[J]. Appl Immunohistochem Mol Morphol, 2014, 22(10): 741-747.